Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 5.87M P/E - EPS this Y -26.60% Ern Qtrly Grth -
Income -4.13M Forward P/E -4.45 EPS next Y 76.10% 50D Avg Chg 12.00%
Sales 2.54M PEG - EPS past 5Y - 200D Avg Chg -8.00%
Dividend N/A Price/Book 0.46 EPS next 5Y - 52W High Chg -61.00%
Recommedations 3.00 Quick Ratio 11.10 Shares Outstanding 1.54M 52W Low Chg 61.00%
Insider Own 19.05% ROA -22.29% Shares Float 1.25M Beta 2.67
Inst Own 1.10% ROE -35.27% Shares Shorted/Prior 2.80K/2.21K Price 3.87
Gross Margin 100.00% Profit Margin -162.78% Avg. Volume 34,535 Target Price -
Oper. Margin -186.87% Earnings Date May 9 Volume 1,113 Change 0.02%
About Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

XBIO Chatroom

User Image Doozio Posted - 4 days ago

$XBIT A) is still $xbio wen chop chop huckleberries becomes 🧠⏰

User Image NMWOLF Posted - 04/22/24

$XBIO Adding here 💎 Dp criteria hit

User Image RallyRaider Posted - 04/22/24

$XBIO put this one on watch. They show great results in combination trial with anti-PD1. Anybody owns this and why?

User Image RAFN Posted - 04/11/24

$XBIO recent

User Image RAFN Posted - 04/11/24

$XBIO 2020 4.42

User Image RAFN Posted - 04/11/24

$XBIO 4.42

User Image ToTheStarsTwits Posted - 04/08/24

$XBIO

User Image ToTheStarsTwits Posted - 4 weeks ago

$XBIO sitting on a starter here

User Image Doozio Posted - 1 month ago

$XBi the list of biotech stonks with under a 100 milly market 🧢 crushed off 2021 highs they gonna pump in 🧠⏰ ? Fookin scrabble bag it! $xbit A) is obviously $xbio.

User Image Doozio Posted - 1 month ago

$XBIO chop chop moar crushed 2021 stonks in 🧠⏰

User Image Mojoo1 Posted - 1 month ago

$XBIO Based on the information provided, it's difficult to definitively determine if the company will need to raise cash in 2024. Factors such as upcoming expenses, investment opportunities, and revenue projections will play a significant role in determining the company's cash needs. However, with a cash position of approximately $9.0 million at the end of 2023 and considering the net loss incurred, the company may need to consider various financing options to support its operations and growth initiatives in 2024.

User Image Mojoo1 Posted - 1 month ago

$XBIO Net Loss: The company experienced a net loss of approximately $4.1 million for the year ending December 31, 2023.Research and Development Expenses: These expenses decreased by $1.3 million, or 26.7%, compared to the previous year, primarily due to a decrease in in-process research and development expenses associated with licensing the DNase platform.Royalty Payments: Royalty payments of approximately $2.5 million were received from a sublicense with Takeda Pharmaceuticals Co. Ltd, representing an approximate 48.8% increase over the same period in 2022.General and Administrative Expenses: These expenses were $3.6 million, decreasing by approximately $0.1 million, or 2.5%, compared to the prior year. The decrease was mainly due to a decrease in employee-related costs, offset by increases in consulting and legal costs.Cash Position: The company ended the year with approximately $9.0 million in cash.

User Image Stock_Titan Posted - 03/22/24

$XBIO Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results https://www.stocktitan.net/news/XBIO/xenetic-biosciences-inc-reports-full-year-2023-financial-lqt5mok7iegp.html

User Image RixtaRox_7Billion Posted - 03/12/24

$XBIO come on over to ALT

User Image Crucial_Update Posted - 03/08/24

$XBIO so done with this turd

User Image brentkhack Posted - 2 months ago

$XBIO @Chieftess is it time again? Chart looking good if this breaks. Will have to DD this again.

User Image bizzy99 Posted - 02/23/24

$XBIO

User Image Phillvsthemarket Posted - 02/22/24

$IBRX Yes … bladder cancer drug approval any minute 🚨 you add now you double or triple here YES OR YES $XBIO once approved. The sector will jump in

User Image stockaceuno Posted - 02/20/24

$XBIO hopefully Xbio is connected with this vaccine

User Image stockaceuno Posted - 02/20/24

$XBIO https://www.xeneticbio.com/news-media/press-releases/detail/94/xenetic-biosciences-inc-announces-collaboration-with

User Image stockaceuno Posted - 02/20/24

$XBIO https://youtu.be/E1FkOaShWEk?si=TcTD4DOY9tzPwcnE

User Image HannahStinson Posted - 3 months ago

$XBIO $KSMT $SYBX $UTSI Started trading over 4 months ago and I lost $3K. Now I've made over $177K+ profits after joining their chat room and using their alerts.. Highly recommended! It's free joining''.,''👓 best-stock-winning-tradesmarket.profitablestocks.vip/

User Image jimsmits Posted - 01/23/24

$XBIO padre was lying

User Image Hombrevertical Posted - 01/22/24

$XBIO Padre Pio told me in a dream that tomorrow it will open at $12. He never makes mistakes.

User Image jimsmits Posted - 01/17/24

$XBIO imagine being a board member - easy street

User Image STCKPRO Posted - 01/17/24

$XBIO NEW ARTICLE : Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform https://www.stck.pro/news/XBIO/72965694/

User Image tradethehalt Posted - 4 months ago

This Morning's Top 5 Gainers Report: $XBIO (0%) $RIOT (0%) $RRR (0%) $GLMD (0%) $TFPN (0%) If we missed a split/reverse split, let us know!

User Image exwallstcfo Posted - 12/28/23

buy the losers for today and tomorrow that will be the big winners next year. ... ENERGY .... SOLAR..... WEED .... BIOTECH .....FINANCIALS ... will finish year up a grateful 38% despite a few big losers $ONCY $TOVX $XBIO

User Image cctranscripts Posted - 12/18/23

Xenetic Biosciences, Inc. director just declared owning 0 shares of Xenetic Biosciences, Inc. https://www.conferencecalltranscripts.org/summary/?id=12801909 $XBIO

User Image cctranscripts Posted - 12/18/23

Xenetic Biosciences, Inc. director was just granted 2,500 options https://www.conferencecalltranscripts.org/summary/?id=12801935 $XBIO

Analyst Ratings
HC Wainwright & Co. Neutral May 16, 23